Cite
HARVARD Citation
Minari, R. et al. (2022). PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors. Tumori. 108 (1), pp. 47-55. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Minari, R. et al. (2022). PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors. Tumori. 108 (1), pp. 47-55. [Online].